KOSDAQMedia & Entertainment0010S0

Wise Planet Company

₩5,290▼ 2.22%2026-11-18 close
Market Cap
₩53B
Turnover
₩200M
Volume
30K
Shares out.
10M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Profit recovery riding one brand

Third-quarter 2026 DART figures show modest sales growth but lower operating profit, leaving the durability of post-listing margin gains as the key question.

  1. 1

    On DART figures for the third quarter of 2026, sales reached KRW 18.2 billion, up 1.8% year on year, while operating profit fell 19.4% to KRW 1.94 billion.

  2. 2

    In the first half of 2026, operating profit rose 131.2%, a trend that contrasts with the third-quarter decline.

  3. 3

    Dr.Piel accounted for 65.6% of cumulative sales through the third quarter of 2026, underscoring a high degree of brand concentration.

  4. 4

    New shares issued during the listing brought in roughly KRW 16.2 billion of capital, widening the company's financial flexibility.

  5. 5

    The share price of KRW 5,430 sits below the KRW 12,000 offering price, and the market capitalization stands at KRW 54.4 billion.

02

Business structure

Wise Planet Company started as a digital advertising agency, but it used consumer response and purchase data gathered through performance marketing to plan its own products, gradually shifting its center of gravity toward owned brands.

Its flagship brands are Dr.Piel, a filter shower head and household goods brand, Nujam, a bedding brand, and Irenol, a cosmetics brand. It also runs Citify, a small appliance brand, and Chaesikjuuiui, a gentle-formula cosmetics brand.

The company does not own manufacturing facilities and outsources all products, handling brand planning, marketing, and sales itself. Customer data collected through a self-operated D2C mall feeds CRM and marketing, while its in-house platform WAPL manages sales, inventory, and delivery.

Consolidated sales for 2025 were KRW 64.8 billion, down 6.5% year on year, reflecting the exit from low-margin live shopping channels. Operating profit for 2025 was about KRW 6.3 billion, roughly flat from the prior year.

Dr.Piel generated KRW 33.7 billion of sales through the third quarter of 2026, or 65.6% of the total. Compared with advertising agency peers such as Cheil Worldwide and Innocean Worldwide, the company's earnings depend more heavily on product sales margins than on agency fees.

03

Recent trends

On DART figures for the third quarter of 2026, sales came to KRW 18.2 billion, up 1.8% from the same period a year earlier. Operating profit for the same period was KRW 1.94 billion, down 19.4%, and net income was KRW 1.2 billion, down 58.5%.

In a statement on November 17, 2026, the company presented cumulative third-quarter sales of KRW 51.3 billion and operating profit of KRW 5.0 billion, citing year-on-year gains of 5.0% and 33.9%, respectively. Cumulative operating margin was 9.7%, according to the company's disclosure.

The company attributed the cumulative improvement mainly to strong sales of Dr.Piel. For the first half of 2026, consolidated sales were KRW 33.2 billion, operating profit KRW 3.0 billion, and net income KRW 3.7 billion, up 6.8%, 131.2%, and 155.2% year on year.

The first-half operating margin rose from 4.2% to 9.2%, and first-half Dr.Piel sales reached KRW 21.0 billion, up 39%. Operating cash flow for the cumulative third quarter was KRW 5.5 billion, up 64.2% year on year. Shares opened the listing day on September 23, 2026 at as high as KRW 42,800 intraday.

As of 14:23 KST on November 18, 2026, the share price was KRW 5,430, down 1.45% from the previous close, with trading value of KRW 0.2 billion and market capitalization of KRW 54.4 billion.

04

Outlook

The company has said it will use its listing proceeds for entry into the U.S. premium water care market, expansion of the Dr.Piel and Nujam product lines, new product launches, and strategic acquisitions.

KRW 4.5 billion has been allocated to domestic experience hubs and overseas self-operated malls for 2026 through 2028. Another KRW 5.7 billion is designated as working capital for domestic brand marketing, global content production, and hiring for overseas sales and marketing.

The first half of 2026 was driven by repeat purchases of Dr.Piel, while the third quarter showed a decline in operating profit, so the trend has been mixed. One press report noted that new product contributions will become more important given how heavily sales rely on Dr.Piel.

Press coverage also flagged that if Dr.Piel sales slow, the extent to which other brands can offset the gap will become a key variable. The 2026 annual business report will show quarterly cost structure, sales by brand, and the use of listing proceeds. The timing and scale of overseas expansion in reported results will become clearer through future disclosures.

05

Bull factors

Repeat purchases lift Dr.Piel

First-half 2026 Dr.Piel sales reached KRW 21.0 billion, up 39% year on year. Growing repeat purchases of the filter replacement line also improved marketing efficiency. Nujam's contribution margin rose from 8.1% to 17.4%, adding to profitability gains.

Listing capital and cash flow

Cumulative operating cash flow through the third quarter of 2026 was KRW 5.5 billion, up 64.2% year on year. New shares issued in the September listing added about KRW 16.2 billion of capital, lifting total equity to KRW 62.4 billion at quarter-end. A KB Securities analyst pointed to a net cash position of about KRW 38.0 billion.

North American push and D2C build-out

The company has said listing proceeds will fund entry into the U.S. premium water care market and the build-out of Amazon and self-operated D2C channels. KRW 4.5 billion is allocated to domestic experience hubs and overseas self-operated malls for 2026 through 2028. North American expansion was again highlighted in the company's November 2026 statement.

06

Bear factors

Third-quarter operating profit decline

Operating profit for the third quarter of 2026 fell 19.4% to KRW 1.94 billion on DART figures. Net income fell 58.5% to KRW 1.2 billion, so both profit measures weakened. Sales rose 1.8% to KRW 18.2 billion, but the top-line gain did not carry through to profit. The drivers of the quarterly decline can be traced through quarterly cost breakdowns in the 2026 annual report.

Concentration on Dr.Piel

Dr.Piel accounted for 65.6% of cumulative sales through the third quarter of 2026, which points to high brand concentration. Press coverage noted that if sales of this brand slow, the extent to which other brands can fill the gap becomes a key earnings variable. Dr.Piel generated KRW 36.0 billion of sales in 2025.

Stagnant top-line growth

A KB Securities analyst flagged stagnant sales and earnings growth over the past three years as a risk factor. Consolidated sales for 2025 fell 6.5% to KRW 64.8 billion, reflecting the exit from low-margin live shopping channels. First-half 2026 sales grew only 6.8%.

07

Risk factors

Market and liquidity

The share price, which reached KRW 42,800 intraday on the listing day of September 23, 2026, now stands at KRW 5,430. The gap from the KRW 12,000 offering price points to pronounced price volatility. Trading value is about KRW 0.2 billion, indicating thin turnover. Market capitalization is KRW 54.4 billion.

Macro and consumer demand

Household goods demand is shaped by household sentiment and price trends. Higher-priced household products such as Dr.Piel may see replacement cycles lengthen during economic slowdowns. Rising advertising costs per customer could also reduce the efficiency of D2C marketing.

Outsourced production and channel dependence

Because the company outsources all products without owned manufacturing, it is exposed to supplier quality, delivery timing, and cost swings. A sales structure centered on its own mall and online platforms is sensitive to changes in platform fees and advertising policies. In North America, local regulation and distribution terms would add further variables.

08

Overall view

Wise Planet Company reported its first quarterly results since its KOSDAQ listing in September 2026. On DART figures, third-quarter sales rose while operating profit declined.

The first half showed clear margin improvement, with sales up 6.8% and operating profit up 131.2%, much of it driven by repeat purchases and marketing efficiency at Dr.Piel. With that brand at 65.6% of cumulative sales, brand concentration remains the central variable for earnings volatility.

The roughly KRW 16.2 billion of capital raised in the listing has expanded financial flexibility, and cumulative operating cash flow has also grown year on year.

North American entry and new product launches are the company's next growth vectors, and their contribution to results will become visible in future disclosures. The bull case rests on margin gains and financial capacity, while the bear case rests on the third-quarter profit decline and brand concentration.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. mt.co.kr
  2. bloter.net
  3. gukjenews.com
  4. biz.heraldcorp.com
  5. the-stock.kr
  6. newstong.co.kr
  7. pinpointnews.co.kr
  8. sentv.co.kr
  9. view.asiae.co.kr
  10. etoday.co.kr
  11. newspim.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis